ABVC BIOPHARMA, INC. (American BriVision Holding Corporation) - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 8, 2021, by American BriVision (Holding) Corporation (also referenced as ABVC BIOPHARMA, INC. in metadata). The registrant is incorporated in Nevada and maintains principal executive offices in Fremont, California. The report serves as a Regulation FD disclosure regarding the notification of an upcoming annual shareholder meeting.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notification and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary event reported is the scheduling of the annual shareholder meeting.
Guidance, Outlook, and Management Commentary
- Annual Meeting: The Company will hold its annual shareholder meeting on February 8, 2021.
- Format: Due to coronavirus pandemic concerns, the meeting will be held virtually via a Zoom video webinar with no physical in-person attendance.
- Time: 9:30 p.m. local time in Taiwan (8:30 a.m. EST).
- Purpose: To consider and vote upon several proposals detailed in the attached Notice to Shareholders (Exhibit 99.1).
- Future Disclosure: Voting results will be disclosed in an amendment to this report following the meeting.
Key Facts for Investor Verification
- Verify the specific proposals to be voted on by reviewing the attached Notice to Shareholders (Exhibit 99.1).
- Confirm the virtual meeting access link and registration requirements prior to February 8, 2021.
- Monitor for a subsequent 8-K amendment to obtain the official voting results.
- Note that the information in Item 7.01 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.